The Canadian government has given a scathing assessment of Eli Lilly’s patenting practices in its formal response to the pharmaceutical company’s CAD $500 million ($401 million) lawsuit against it.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Eli Lilly, Canadian government, NAFTA, promise of utility, Special 301 report, patent
